200 related articles for article (PubMed ID: 31927212)
1. The CXCR2/CXCL2 signalling pathway - An alternative therapeutic approach in high-grade glioma.
Acker G; Zollfrank J; Jelgersma C; Nieminen-Kelhä M; Kremenetskaia I; Mueller S; Ghori A; Vajkoczy P; Brandenburg S
Eur J Cancer; 2020 Feb; 126():106-115. PubMed ID: 31927212
[TBL] [Abstract][Full Text] [Related]
2. Programmed Cell Death 10 Mediated CXCL2-CXCR2 Signaling in Regulating Tumor-Associated Microglia/Macrophages Recruitment in Glioblastoma.
Zhang Q; Wang J; Yao X; Wu S; Tian W; Gan C; Wan X; You C; Hu F; Zhang S; Zhang H; Zhao K; Shu K; Lei T
Front Immunol; 2021; 12():637053. PubMed ID: 34108959
[TBL] [Abstract][Full Text] [Related]
3. Combining TMZ and SB225002 induces changes of CXCR2 and VEGFR signalling in primary human endothelial cells
Urbantat RM; Jelgersma C; Vajkoczy P; Brandenburg S; Acker G
Oncol Rep; 2022 Sep; 48(3):. PubMed ID: 35856448
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Associated Microglia/Macrophages as a Predictor for Survival in Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance Overcoming Strategy by Combination Therapy.
Urbantat RM; Jelgersma C; Brandenburg S; Nieminen-Kelhä M; Kremenetskaia I; Zollfrank J; Mueller S; Rubarth K; Koch A; Vajkoczy P; Acker G
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681839
[TBL] [Abstract][Full Text] [Related]
5. Resident microglia rather than peripheral macrophages promote vascularization in brain tumors and are source of alternative pro-angiogenic factors.
Brandenburg S; Müller A; Turkowski K; Radev YT; Rot S; Schmidt C; Bungert AD; Acker G; Schorr A; Hippe A; Miller K; Heppner FL; Homey B; Vajkoczy P
Acta Neuropathol; 2016 Mar; 131(3):365-78. PubMed ID: 26718201
[TBL] [Abstract][Full Text] [Related]
6. The CXCL2/IL8/CXCR2 Pathway Is Relevant for Brain Tumor Malignancy and Endothelial Cell Function.
Urbantat RM; Blank A; Kremenetskaia I; Vajkoczy P; Acker G; Brandenburg S
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807899
[TBL] [Abstract][Full Text] [Related]
7. CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy-Resistant Glioblastoma.
Angara K; Borin TF; Rashid MH; Lebedyeva I; Ara R; Lin PC; Iskander A; Bollag RJ; Achyut BR; Arbab AS
Neoplasia; 2018 Oct; 20(10):1070-1082. PubMed ID: 30236892
[TBL] [Abstract][Full Text] [Related]
8. Cell-specific regulatory effects of CXCR2 on cholestatic liver injury.
Konishi T; Schuster RM; Goetzman HS; Caldwell CC; Lentsch AB
Am J Physiol Gastrointest Liver Physiol; 2019 Dec; 317(6):G773-G783. PubMed ID: 31604030
[TBL] [Abstract][Full Text] [Related]
9. Rebound increases in chemokines by CXCR2 antagonist in breast cancer can be prevented by PKCδ and PKCε activators.
Erin N; Tavşan E; Akdeniz Ö; Isca VMS; Rijo P
Cytokine; 2021 Jun; 142():155498. PubMed ID: 33773907
[TBL] [Abstract][Full Text] [Related]
10. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
Devapatla B; Sharma A; Woo S
PLoS One; 2015; 10(9):e0139237. PubMed ID: 26414070
[TBL] [Abstract][Full Text] [Related]
11. CXCL2-CXCR2 axis mediates αV integrin-dependent peritoneal metastasis of colon cancer cells.
Lepsenyi M; Algethami N; Al-Haidari AA; Algaber A; Syk I; Rahman M; Thorlacius H
Clin Exp Metastasis; 2021 Aug; 38(4):401-410. PubMed ID: 34115261
[TBL] [Abstract][Full Text] [Related]
12. Hepatocyte signaling through CXC chemokine receptor-2 is detrimental to liver recovery after ischemia/reperfusion in mice.
Kuboki S; Shin T; Huber N; Eismann T; Galloway E; Schuster R; Blanchard J; Edwards MJ; Lentsch AB
Hepatology; 2008 Oct; 48(4):1213-23. PubMed ID: 18688883
[TBL] [Abstract][Full Text] [Related]
13. IL-8/CXCR2 Signalling Promotes Cell Proliferation in Oesophageal Squamous Cell Carcinoma and Correlates With Poor Prognosis.
Inoue M; Takeuchi H; Matsuda S; Nishi T; Fukuda K; Nakamura R; Takahashi T; Wada N; Kawakubo H; Kitagawa Y
Anticancer Res; 2021 Feb; 41(2):783-794. PubMed ID: 33517283
[TBL] [Abstract][Full Text] [Related]
14. CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer.
Zhang H; Ye YL; Li MX; Ye SB; Huang WR; Cai TT; He J; Peng JY; Duan TH; Cui J; Zhang XS; Zhou FJ; Wang RF; Li J
Oncogene; 2017 Apr; 36(15):2095-2104. PubMed ID: 27721403
[TBL] [Abstract][Full Text] [Related]
15. Autocrine control of MIP-2 secretion from metastatic breast cancer cells is mediated by CXCR2: a mechanism for possible resistance to CXCR2 antagonists.
Erin N; Nizam E; Tanrıöver G; Köksoy S
Breast Cancer Res Treat; 2015 Feb; 150(1):57-69. PubMed ID: 25682075
[TBL] [Abstract][Full Text] [Related]
16. Blockage of CXCR2 suppresses tumor growth of intrahepatic cholangiocellular carcinoma.
Sueoka H; Hirano T; Uda Y; Iimuro Y; Yamanaka J; Fujimoto J
Surgery; 2014 Apr; 155(4):640-9. PubMed ID: 24582495
[TBL] [Abstract][Full Text] [Related]
17. CXCR2 is essential for cerebral endothelial activation and leukocyte recruitment during neuroinflammation.
Wu F; Zhao Y; Jiao T; Shi D; Zhu X; Zhang M; Shi M; Zhou H
J Neuroinflammation; 2015 May; 12():98. PubMed ID: 25990934
[TBL] [Abstract][Full Text] [Related]
18. Selective blocking of CXCR2 prevents and reverses atrial fibrillation in spontaneously hypertensive rats.
Zhang YL; Teng F; Han X; Li PB; Yan X; Guo SB; Li HH
J Cell Mol Med; 2020 Oct; 24(19):11272-11282. PubMed ID: 32812337
[TBL] [Abstract][Full Text] [Related]
19. Decrease of VEGF-A in myeloid cells attenuates glioma progression and prolongs survival in an experimental glioma model.
Osterberg N; Ferrara N; Vacher J; Gaedicke S; Niedermann G; Weyerbrock A; Doostkam S; Schaefer HE; Plate KH; Machein MR
Neuro Oncol; 2016 Jul; 18(7):939-49. PubMed ID: 26951383
[TBL] [Abstract][Full Text] [Related]
20. High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras.
Wislez M; Fujimoto N; Izzo JG; Hanna AE; Cody DD; Langley RR; Tang H; Burdick MD; Sato M; Minna JD; Mao L; Wistuba I; Strieter RM; Kurie JM
Cancer Res; 2006 Apr; 66(8):4198-207. PubMed ID: 16618742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
